Barber Financial Group Inc. Trims Position in Johnson & Johnson (NYSE:JNJ)

Barber Financial Group Inc. decreased its position in shares of Johnson & Johnson (NYSE:JNJ – Get Rating) by 8.5% during the 1st quarter, according to its most recent disclosure with the SEC. The firm owned 1,530 shares of the company’s stock after selling 143 shares during the period. Barber Financial Group Inc.’s holdings in Johnson & Johnson were worth $271,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently made changes to their positions in the stock. Magnolia Capital Management Ltd. grew its holdings in Johnson & Johnson by 0.5% during the first quarter. Magnolia Capital Management Ltd. now owns 11,162 shares of the company’s stock valued at $1,978,000 after purchasing an additional 55 shares during the period. Capital Investment Counsel Inc lifted its position in shares of Johnson & Johnson by 0.8% in the fourth quarter. Capital Investment Counsel Inc now owns 7,796 shares of the company’s stock valued at $1,334,000 after acquiring an additional 59 shares in the last quarter. Beaton Management Co. Inc. lifted its position in shares of Johnson & Johnson by 0.3% in the fourth quarter. Beaton Management Co. Inc. now owns 22,250 shares of the company’s stock valued at $3,806,000 after acquiring an additional 60 shares in the last quarter. Corsicana & Co. lifted its position in shares of Johnson & Johnson by 0.4% in the first quarter. Corsicana & Co. now owns 15,553 shares of the company’s stock valued at $2,756,000 after acquiring an additional 60 shares in the last quarter. Finally, Iron Horse Wealth Management LLC lifted its position in shares of Johnson & Johnson by 29.9% in the fourth quarter. Iron Horse Wealth Management LLC now owns 265 shares of the company’s stock valued at $45,000 after acquiring an additional 61 shares in the last quarter. 68.78% of the stock is currently owned by institutional investors and hedge funds.

In related news, EVP Kathryn E. Wengel sold 40,000 shares of the stock in a transaction that occurred on Friday, June 10th. The stock was sold at an average price of $173.00, for a total value of $6,920,000.00. Following the transaction, the executive vice president now owns 71,311 shares of the company’s stock, valued at $12,336,803. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider William Hait sold 29,699 shares of the stock in a transaction that occurred on Thursday, April 21st. The stock was sold at an average price of $183.58, for a total value of $5,452,142.42. Following the completion of the transaction, the insider now directly owns 80,236 shares in the company, valued at approximately $14,729,724.88. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 78,161 shares of company stock worth $13,895,302. Insiders own 0.35% of the company’s stock.

JNJ has been the topic of several research analyst reports. Raymond James boosted their price objective on Johnson & Johnson from $195.00 to $196.00 and gave the company an “outperform” rating in a research report on Wednesday, April 20th. Sanford C. Bernstein downgraded Johnson & Johnson from an “outperform” rating to a “market perform” rating and boosted their target price for the stock from $180.00 to $183.00 in a research report on Wednesday, March 16th. Morgan Stanley decreased their target price on Johnson & Johnson from $175.00 to $173.00 and set an “equal weight” rating on the stock in a research report on Wednesday, April 6th. The Goldman Sachs Group boosted their target price on Johnson & Johnson from $163.00 to $181.00 and gave the stock a “neutral” rating in a research report on Tuesday, April 12th. Finally, Bank of America began coverage on Johnson & Johnson in a research report on Wednesday, March 2nd. They issued a “neutral” rating on the stock. Four analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $190.50.

Shares of JNJ stock opened at $175.74 on Thursday. Johnson & Johnson has a 1 year low of $155.72 and a 1 year high of $186.69. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.39 and a quick ratio of 1.14. The stock’s 50 day simple moving average is $177.66 and its two-hundred day simple moving average is $173.09. The company has a market cap of $462.44 billion, a PE ratio of 23.68, a price-to-earnings-growth ratio of 3.35 and a beta of 0.66.

Johnson & Johnson (NYSE:JNJ – Get Rating) last released its earnings results on Tuesday, April 19th. The company reported $2.67 EPS for the quarter, beating analysts’ consensus estimates of $2.60 by $0.07. The firm had revenue of $23.43 billion for the quarter, compared to analysts’ expectations of $23.62 billion. Johnson & Johnson had a return on equity of 36.59% and a net margin of 20.90%. The company’s quarterly revenue was up 5.0% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.59 earnings per share. Equities research analysts expect that Johnson & Johnson will post 10.23 EPS for the current year.

The firm also recently announced a quarterly dividend, which was paid on Tuesday, June 7th. Stockholders of record on Tuesday, May 24th were paid a dividend of $1.13 per share. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.06. The ex-dividend date was Monday, May 23rd. This represents a $4.52 dividend on an annualized basis and a dividend yield of 2.57%. Johnson & Johnson’s dividend payout ratio is currently 60.92%.

About Johnson & Johnson (Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Featured Articles